Detail akcie Poxel online

Business Summary: Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Poxel SA revenues increased 88% to EUR2.2M. Net loss decreased 64% to EUR2.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Sumitomo Pharma segment loss decrease of 47% to EUR2M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.17 to -EUR0.05.